The vaccine has been shown to prolong the life of patients with aggressive brain cancer Cancer research

The vaccine has been shown to prolong the life of patients with aggressive brain cancer Cancer research

The world’s first vaccine to treat deadly cancerous brain tumors could potentially give patients years of extra life, a global clinical trial has concluded.

A senior NHS doctor who was one of the trial’s principal investigators said the evidence showed DCVax resulted in a “stunning” improvement in patient survival.

The breakthrough could benefit the 2,500 people a year in the UK who are diagnosed glioblastoma , the most common form of brain cancer and one of the most aggressive. People with this disease live an average of only 12-18 months after diagnosis, and some even less.

One patient in A multicenter global study with 331 people lived more than eight years after receiving DCVax. In Britain, 53-year-old Nigel French is still alive seven years after he got it.

“The overall results are astounding,” he said Ashkan prof. Keyoumara, a neurosurgeon at King’s College Hospital in London who was the European principal investigator for the trial. “The final results of this phase 3 trial … offer fresh hope to patients battling glioblastoma.

“The vaccine has been shown to prolong life and, interestingly, in patients traditionally thought to have a worse prognosis,” such as the elderly and people for whom surgery was not an option, he added.

If approved by medical regulators, DCVax would be the first new treatment in 17 years for patients with newly diagnosed glioblastoma and the first in 27 years for people in whom it has come back.

The researchers found that newly diagnosed patients who received the vaccine survived an average of 19.3 months, compared to 16.5 months for those who received a placebo.

Participants with recurrent glioblastoma who had DCVax lived an average of 13.2 months after receiving it, compared to just 7.8 months for those who did not.

Overall, 13% of people who received it lived at least five years after diagnosis, compared to just 5.7% of those in the control group, according to trial results published Thursday in the Journal of American Medical. Oncology Association.

The vaccine is a form of immunotherapy, in which the body’s immune system is programmed to find and attack the tumor. The first was developed for the treatment of brain tumors.

“The vaccine works by stimulating the patient’s own immune system to fight the patient’s tumor. It provides a personalized solution, working with the patient’s immune system, which is the most intelligent system known to man,” said Ashkan.

“The vaccine is made by combining proteins from the patient’s tumor with his white blood cells. This educates the white cells to recognize the tumor.

“When the vaccine is administered, those educated white blood cells then help the rest of the patient’s immune system recognize the tumor as something to fight and destroy. Almost like training a sniffer dog.”

The vaccine is not yet available on the NHS. But Northwest Biotherapeutics, the US company that makes it, plans to seek regulatory approval to make it available.

benevolence Brain tumor research he said that “patients who have been deprived of new clinical options for too long” should have access to treatment to prolong their lives.

“DCVax represents the first emerging therapy to be proven effective in the treatment of glioblastoma since temozolomide chemotherapy in 2005, and what the brain tumor community hopes is that it will become affordable, perhaps the standard of care – so available on the NHS.” , said Dr Karen Noble, the charity’s director of research, policy and innovation.

“The average survival time for glioblastoma is devastatingly short – only 12 to 18 months. Stories like Mr. French’s are rare but incredibly welcome. We are very encouraged by the final results of this trial,” she added.

Twenty of the 331 patients in the eight-year trial were in the UK, either at King’s Hospital or University College London. A total of 232 participants received DCVax and 99 received placebo. All 331 had surgery followed by radiotherapy and chemotherapy to remove as much of their tumor as possible, which is the standard treatment for glioblastoma.

dr. Henry Stennett, head of research information at Cancer Research UK, said: “What is particularly exciting is that [the vaccine] it can improve results for people who don’t usually respond well to therapy. Although it still needs to go through strict regulatory approvals, it could be a big step forward in defeating this type of brain tumor.”



Leave a Comment

Your email address will not be published. Required fields are marked *